What’s Propelling Pavmed Inc (NASDAQ:PAVM) After Higher Shorts Reported?

August 9, 2018 - By Carolyn Hewitt

The stock of Pavmed Inc (NASDAQ:PAVM) registered an increase of 59.6% in short interest. PAVM’s total short interest was 55,700 shares in August as published by FINRA. Its up 59.6% from 34,900 shares, reported previously. With 37,800 shares average volume, it will take short sellers 2 days to cover their PAVM’s short positions. The short interest to Pavmed Inc’s float is 0.92%.

The stock decreased 1.40% or $0.02 during the last trading session, reaching $1.41. About 318,417 shares traded. PAVmed Inc. (NASDAQ:PAVM) has declined 72.52% since August 9, 2017 and is downtrending. It has underperformed by 85.09% the S&P500.

PAVmed Inc. operates as a medical device firm in the United States. The company has market cap of $37.38 million. The Company’s product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device. It currently has negative earnings. The firm was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015.

More important recent PAVmed Inc. (NASDAQ:PAVM) news were published by: Seekingalpha.com which released: “PAVmed: Medical Device Innovator With A Robust Pipeline” on July 27, 2018, also Nasdaq.com published article titled: “PAVmed Inc. to Hold SECOND QUARTER FINANCIAL RESULTS AND BUSINESS UPDATE Conference Call on …”, Streetinsider.com published: “PAVmed (PAVM) Announces Business Update” on July 25, 2018. More interesting news about PAVmed Inc. (NASDAQ:PAVM) was released by: Globenewswire.com and their article: “PAVmed Provides Business Update” with publication date: July 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.